Browse News
Filter News
Found 273 articles
-
Opthea Appoints John Han, PharmD, as VP Medical AffairsBrings extensive experience in retinal and ophthalmology diseases
4/8/2024
Opthea Limited announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024.
-
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
3/18/2024
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023.
-
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
2/28/2024
Adverum Biotechnologies, Inc. announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Ophthalmology Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:10 a.m. ET.
-
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/12/2024
Adverum Biotechnologies, Inc. today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13th , 2024 at 12:00 p.m. ET.
-
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
2/8/2024
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with wet age-related macular degeneration (AMD).
-
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
2/5/2024
Adverum Biotechnologies, Inc. today announced that it has agreed to sell approximately 106.25 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $1.20, representing a premium of approximately 20% to Adverum’s 30-day volume-weighted average price.
-
Opthea Strengthens Team with Key Clinical and Regulatory Hires
2/1/2024
Opthea Limited announced the appointment of Julie Clark, MD, MS, as Senior Vice President, Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024.
-
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
2/1/2024
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) on Thursday, February 8th, 2024 at 8:00am ET.
-
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
1/29/2024
Adverum Biotechnologies, Inc. today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the company’s chief scientific officer.
-
BioMarin Announces Governance Enhancements and Value Creation Initiatives
12/20/2023
BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, announced several initiatives to enhance corporate governance and long-term shareholder value creation.
-
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
12/7/2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024.
-
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
11/28/2023
Adverum Biotechnologies, Inc. announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m. ET in Miami, Florida.
-
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
11/9/2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.
-
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
11/6/2023
Adverum Biotechnologies, Inc. today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023.
-
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
11/4/2023
Adverum Biotechnologies, Inc. announced updated data from the OPTIC extension study of patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, California.
-
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
9/26/2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced initial aflibercept protein expression data from its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD).
-
Nanoscope Therapeutics Strengthens Clinical and Regulatory Expertise With Appointment of Samuel Barone, M.D., as Chief Medical Officer
9/21/2023
Nanoscope Therapeutics Inc. announced the appointment of Samuel Barone, M.D., an accomplished leader in the pharmaceutical space and former FDA official, as Chief Medical Officer.
-
Adverum Biotechnologies to Participate in Upcoming Investor Conferences - September 21, 2023
9/21/2023
Adverum Biotechnologies, Inc., a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced that Adverum Biotechnologies will present at the following upcoming investor conferences.
-
Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Linda Rubinstein, chief financial officer of Adverum Biotechnologies, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023.
-
Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
8/21/2023
Adverum Biotechnologies, Inc. announced that R. Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum as the company’s chief technology officer.